Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02349295 · ClinicalTrials.gov registry record · Phase 3
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 363
- Enrollment target
NCT02349295 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 363 participants.
The verdict
NCT02349295, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 363 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate how effective and safe the study drug known as ixekizumab is in participants with active psoriatic arthritis.
Interventions
- DRUG Placebo
- DRUG Ixekizumab 80 mg Q4W
- DRUG Ixekizumab 80 mg Q2W
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 363 participants |
| Start Date | 2014-12-31 |
| Est. Completion | 2019-06-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02349295
The ClinicalTrials.gov registry entry for NCT02349295 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 363 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02349295 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02349295 about?
NCT02349295 is a clinical study titled "A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis". The main purpose of this study is to evaluate how effective and safe the study drug known as ixekizumab is in participants with active psoriatic arthritis.
What is the current status of trial NCT02349295?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 363 participants. The study started on 2014-12-31. Estimated completion is 2019-06-26.
What interventions are being tested in trial NCT02349295?
The interventions under investigation include: Placebo (DRUG), Ixekizumab 80 mg Q4W (DRUG), Ixekizumab 80 mg Q2W (DRUG).
Who is sponsoring clinical trial NCT02349295?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.